Application

Anti-GHRH (Somatoliberin) Antibody, Cat. No. ABN993, is a highly specific sheep polyclonal antibody that targets Somatoliberin (GHRH) and has been tested in Immunofluorescence, Immunohistochemistry (Paraffin), and Radioimmunoassay.

Research CategoryNeuroscience

Radioimmunoassay Analysis: A representative lot detected GHRH (Somatoliberin) in Radioimmunoassay applications (Tannenbaum, G.S., et. al. (1990). Endocrinology. 127(6):3087-95).

Immunohistochemistry Analysis: A representative lot detected GHRH (Somatoliberin) in Immunohistochemistry applications (Tannenbaum, G.S., et. al. (1990). Endocrinology. 127(5):2551-60; Epelbaum, J., et. al. (1989). J Neuroendocrinol. 1(2):109-15).

Immunofluorescence Analysis: A representative lot detected GHRH (Somatoliberin) in Immunofluorescence applications (Stroh, T., et. al. (2009). J Neurosci. 29(25):8198-205).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Somatoliberin (UniProt: P09916; also known as Growth hormone-releasing factor, GRF, Growth hormone-releasing hormone, GHRH) is encoded by the Ghrh gene (Gene ID: 29446) in rat. GHRH F is released by the hypothalamus and acts on the adenohypophyse to stimulate the secretion of growth hormone. The release of growth hormone from pituitary gland depends of the interplay between the stimulatory action of GHRH and inhibitory action of somatotropin release inhibiting factor (SRiF) or somatostatin. These two neurohormones are shown to be released in a reciprocal manner from the median eminence into the portal circulation and result in ultradian rhythmic release pattern of growth hormone.. Post-translational removal of the signal peptide (aa 1-19) and the two propeptide sequences (aa 20-30) and aa 75-104) releases the 43 aa mature Somatoliberin (aa 31-73), which functions as a ligand to stimulate growth hormone (GH) release from the pituitary. Variant receptors for GHRH have been found in several types of tumors, and antagonists of these receptors are shown to block the growth of the tumors. Defects in Ghrh gene are a known to cause of dwarfism, while hypersecretion of the encoded GHRH can lead to gigantism.

Immunogen

BSA-conjugated synthetic linear peptide corresponding to the first 29 amino acids from rat Somatoliberin (GHRH).

Epitope: N-terminus

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Format: Unpurified

Sheep polyclonal antiserum with 0.01% sodium azide.

Unpurified

Quality

Evaluated by Immunohistochemistry (Paraffin) in mouse brain lateral hypothalamic region.

Immunohistochemistry Analysis: A 1:2,000 dilution of this antibody detected GHRH (Somatoliberin) in mouse brain lateral hypothalamic region.

Specificity

This sheep polyclonal antibody detects somatolierin (GHRH) in mouse and rat brain sections. It targets an epitope within the first 29 amino acids.

Storage and Stability

Stable for 1 year at -20°C from date of receipt.

Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Target description

12.27 kDa calculated.